Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Non-Current Debt (2020 - 2022)

Ensysce Biosciences (ENSC) has disclosed Non-Current Debt for 3 consecutive years, with $140148.0 as the latest value for Q4 2022.

  • On a quarterly basis, Non-Current Debt fell 96.16% to $140148.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $140148.0, a 96.16% decrease, with the full-year FY2022 number at $140148.0, down 96.16% from a year prior.
  • Non-Current Debt was $140148.0 for Q4 2022 at Ensysce Biosciences, down from $1.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.7 million in Q4 2021 to a low of $137317.0 in Q2 2022.
  • A 3-year average of $943868.4 and a median of $566278.0 in 2020 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: skyrocketed 545.04% in 2021, then crashed 96.16% in 2022.
  • Ensysce Biosciences' Non-Current Debt stood at $566288.0 in 2020, then surged by 545.04% to $3.7 million in 2021, then plummeted by 96.16% to $140148.0 in 2022.
  • Per Business Quant, the three most recent readings for ENSC's Non-Current Debt are $140148.0 (Q4 2022), $1.4 million (Q3 2022), and $137317.0 (Q2 2022).